Physician profile
Amir Behdad
NPI 1497978902
$204,317.09
in general payments reported to CMS, 2019-2025
7 companies · $51K in 2025
The $51K reported for 2025 was more than what 98% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,410 · 2020: $1,024 · 2021: $26K · 2022: $52K · 2023: $43K · 2024: $26K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $88K · Travel and Lodging: $23K · Consulting Fee: $5,915 · Food and Beverage: $1,779 · Education: $1,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,112.50 |
| Travel and Lodging | $23,016.38 |
| Consulting Fee | $5,915.00 |
| Food and Beverage | $1,778.59 |
| Education | $1,423.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $192,069.13 | 2021-2025 | |
| Servier Pharmaceuticals LLC | $4,016.91 | 2024 | |
| Pfizer INC. | $2,960.00 | 2019 | |
| Leica Microsystems INC. | $2,750.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,474.00 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $23.65 | 2023 | |
| Aimmune Therapeutics, INC. | $23.40 | 2025 | Vowst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Behdad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.